Cannabis Pharmacology: Peer-Reviewed Research Consensus
Overview
Research on cannabis pharmacology is limited — only 22 studies are available in the literature (2025–2026). Conclusions should be considered preliminary and may evolve as more research is conducted. Key findings with strong support include: a rigorous crossover trial found cbd had no effect on brain excitability or sedation at either low or high doses, suggesting its anti-epileptic benefits may come from drug interactions rather than direct activity. However, several findings remain debated, and the evidence is not uniform across all areas. Given the small evidence base, readers should interpret these results cautiously.
What the Research Shows
Findings supported by multiple peer-reviewed studies. Stronger evidence means more consistency across study types.
A rigorous crossover trial found CBD had no effect on brain excitability or sedation at either low or high doses, suggesting its anti-epileptic benefits may come from drug interactions rather than direct activity
Moderate EvidenceWhere Scientists Disagree
Areas where research shows conflicting results or ongoing scientific debate.
Analysis of 89 daily cannabis users found that 'Willingness to Take Again' better predicted actual cannabis self-administration than the FDA-recommended 'Drug Liking' measure, suggesting regulatory assessment methods may need updating
Moderate EvidenceCrossover trial of 20 adults found CBD co-administration increased THC's subjective high, impairment, and blood concentrations, while caffeine had minimal effects on THC outcomes
Moderate EvidenceClinical trial of 12 volunteers found novel sublingual, rectal, and vaporizer cannabis products had faster cannabinoid absorption than approved products like Sativex, with comparable safety
Moderate EvidenceFirst study characterizing delta-8-THC's drug interaction potential, finding significant inhibition of CYP2C9 and CYP3A4 liver enzymes with clinically relevant predictions
Moderate EvidenceWhat We Still Don't Know
- Only 0 randomized controlled trials exist out of 22 studies — most evidence is observational or from reviews.
- Sex-specific differences in this area remain understudied.
- With only 22 studies, this remains an emerging research area where conclusions should be considered preliminary.
- Long-term prospective studies tracking outcomes over 5+ years are largely absent from the literature.
- Research on diverse populations (different ages, ethnicities, and medical backgrounds) remains limited.
Evidence Breakdown
Distribution of study types in this research area. Higher-tier evidence (meta-analyses, RCTs) provides stronger conclusions.
Key Studies
The most impactful research in this area.
Mapping How 100+ Cannabis Plant Compounds Interact with the Body
Most cannabis science focuses on just two of 100+ compounds — understanding the full pharmacological landscape could unlock new therapeutic applications and explain the 'entourage effect.'
CBD May Not Have Anti-Seizure Properties On Its Own
If CBD's approved anti-seizure effects are primarily driven by drug interactions with clobazam rather than direct anti-epileptic activity, it fundamentally changes how we understand and prescribe CBD for epilepsy.
New Structural Insights Into How Cannabinoid Receptors Work
Understanding the precise 3D structure of cannabinoid receptors enables drug designers to create medications that target specific receptors more accurately, potentially delivering therapeutic benefits without unwanted psychoactive or immune effects.
THC Kills Pain by Blocking Nerve Signals — Without Involving Cannabis Receptors
NaV1.7 and NaV1.8 are the two most important sodium channels for pain signaling. Finding that THC blocks them directly — like a local anesthetic — provides a completely new framework for developing cannabinoid-based painkillers without psychoactive effects.
'Willingness to Take Again' Better Predicted Cannabis Abuse Potential Than 'Drug Liking'
The FDA uses Drug Liking as the primary measure in abuse potential assessments for new drugs. If this measure is not the best predictor of actual drug-taking behavior for cannabinoids, regulatory evaluations of novel cannabinoid products may need updating.
CBD Increased THC's High and Blood Levels, While Caffeine Had Minimal Impact
Cannabis products premixed with caffeine are increasingly common but have never been studied. The unexpected finding that CBD increases THC's effects and blood levels challenges the common belief that CBD moderates THC's impact.
Research Timeline
How our understanding of this topic has evolved.
2020–present
22 studies published. Includes 1 strong-evidence studies.
About This Consensus
This consensus synthesizes 22 peer-reviewed studies: 4 reviews (18%), 18 other study types (82%). Studies span from the earliest available research through 2025. Evidence strength ratings reflect study design, sample size, and replication across multiple research groups.
This page synthesizes findings from 22 peer-reviewed studies. It is not medical advice. Always consult a healthcare provider for personal health decisions.